We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Offers New Avastin Trial, REMS to Keep MBC Indication
Genentech Offers New Avastin Trial, REMS to Keep MBC Indication
August 17, 2011
Genentech is proposing a clinical trial to assess Avastin with weekly paclitaxel and would power the trial to confirm the progression-free survival (PFS) improvement seen in its initial study of the drug for metastatic breast cancer (MBC).